文献速递肿瘤 PET/CT骨显像与常规 SPECT

18F-FDG PET/CT在孤立性浆细胞瘤中的应用:代谢行为及向多发性骨髓瘤进展

18F-FDG PET/CT in solitary plasmacytoma: metabolic behavior and progression to multiple myeloma.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2017-08-19

研究纳入62例未经治疗的孤立性浆细胞瘤患者,治疗前行18F-FDG PET/CT定性和半定量分析。51例PET阳性,平均SUVbw 8.3±4.7;29例进展为多发性骨髓瘤,平均18.3个月。骨孤立性浆细胞瘤和FDG高摄取病灶更易进展,SUVlbm>5.2和SUVbsa>1.7与进展时间显著相关。

要点

  • 62例孤立性浆细胞瘤中51例18F-FDG PET/CT阳性,平均SUVbw为8.3±4.7。
  • 29例进展为多发性骨髓瘤,平均进展时间18.3个月。
  • 骨孤立性浆细胞瘤和FDG高摄取病灶进展风险更高,SUVlbm>5.2和SUVbsa>1.7与更短进展时间相关。

核心结论

  • 孤立性浆细胞瘤中18F-FDG病理性摄取见于多数病例,且与肿瘤大小独立相关。
  • PET/CT似乎与向多发性骨髓瘤转化的更高风险相关,尤其是18F-FDG高摄取浆细胞瘤和骨孤立性浆细胞瘤。
  • 半定量特征中,SUVlbm>5.2和SUVbsa>1.7与进展至多发性骨髓瘤的时间显著相关。

研究设计与样本

  • 纳入62例在任何治疗前接受18F-FDG PET/CT的孤立性浆细胞瘤患者。
  • 对PET图像进行定性和半定量分析,测量SUVbw、SUVlbm、SUVbsa、MTV和TLG,并与年龄、性别、原发部位和肿瘤大小比较。

主要发现

  • 51例患者18F-FDG PET/CT阳性,平均SUVbw为8.3±4.7、SUVlbm为5.8±2.6、SUVbsa为2±1、MTV为45.4±37、TLG为227±114;其余11例无18F-FDG摄取。
  • FDG高摄取患者的肿瘤大小显著高于无FDG摄取患者,其他特征与FDG摄取无关联。
  • 29例进展为多发性骨髓瘤,平均18.3个月;骨浆细胞瘤患者和18F-FDG高摄取病灶患者更易发生多发性骨髓瘤。
  • 骨孤立性浆细胞瘤患者、18F-FDG高摄取病灶患者、SUVlbm>5.2和SUVbsa>1.7者,进展至多发性骨髓瘤的时间显著更短。

关键数值与推荐

  • SUVlbm>5.2与进展至多发性骨髓瘤的时间显著相关。
  • SUVbsa>1.7与进展至多发性骨髓瘤的时间显著相关。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Solitary plasmacytoma (SP) is a rare plasma-cell neoplasm, which can develop both in skeletal and/or soft tissue and frequently progresses to multiple myeloma (MM). Our aim was to study the metabolic behavior of SP and the role of 18F-FDG-PET/CT in predicting progression to MM. MATERIALS AND METHODS: Sixty-two patients with SP who underwent 18F-FDG-PET/CT before any treatment were included. PET images were qualitatively and semiquantitatively analyzed by measuring the maximum standardized uptake value body weight (SUVbw), lean body mass (SUVlbm), body surface area (SUVbsa), metabolic tumor volume (MTV), total lesion glycolysis (TLG) and compared with age, sex, site of primary disease, and tumor size. RESULTS: Fifty-one patients had positive 18F-FDG-PET/CT (average SUVbw was 8.3 ± 4.7; SUVlbm 5.8 ± 2.6; SUVbsa 2 ± 1; MTV 45.4 ± 37; TLG 227 ± 114); the remaining 11 were not 18F-FDG-avid. Tumor size was significantly higher in patients avid lesions compared to FDG not avid; no other features are associated with FDG-avidity. Progression to MM occurred in 29 patients with an average of 18.3 months; MM was more likely to develop in patients with bone plasmacytoma and in patients with 18F-FDG avid lesion. Time to transformation in MM (TTMM) was significantly shorter in patients with osseous SP, in 18F-FDG avid lesion, for SUVlbm > 5.2 and SUVbsa > 1.7. CONCLUSIONS: 18F-FDG pathological uptake in SP occurred in most cases, being independently associated with tumor size. PET/CT seemed to be correlated to a higher risk of transformation in MM, in particular for 18F-FDG avid plasmacytoma and SBP. Among semiquantitative features, SUVlbm > 5.2 and SUVbsa > 1.7 were significantly correlated with TTMM.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Albano D, Bosio G, Treglia G, et al. 18F-FDG PET/CT in solitary plasmacytoma: metabolic behavior and progression to multiple myeloma. Eur J Nucl Med Mol Imaging. 2017. PMID: 28822997. doi:10.1007/s00259-017-3810-5

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。